Metastatic Castration-Resistant Prostate Cancer Articles | Page 2

Radium-223 Retreatment Shows Promise in mCRPC
A second course of radium-223 was associated with minimal hematologic toxicity and low radiographic bone progression rates in a phase I/II study of men with metastatic castration-resistant prostate cancer.
Challenges in mCRPC Landscape Surround Sequencing, Biomarkers, and PARP Inhibition
Tanya B. Dorff, MD, discusses several important components regarding metastatic castration-resistant prostate cancer treatment, including the addition of novel drugs, optimal therapeutic sequences, and the identification of predictive biomarkers.
LDH a Predictor for OS in mCRPC Following Radium-223
Log LDH was the strongest predictor for overall survival with radium-223 for men with metastatic castration resistant prostate cancer.
PARP Inhibitor Tested in mCRPC
Rucaparib, a drug approved for the treatment of ovarian cancer, might also be used to treat patients with metastatic castration-resistant prostate cancer.
A new drug application has been submitted to the FDA for apalutamide (ARN-509) for the treatment of non-metastatic castration-resistant prostate cancer (CRPC).
FDA Approves Reduced Dose of Cabazitaxel for mCRPC
The FDA has approved a cabazitaxel (Jevtana) regimen of 20 mg/m2 every 3 weeks in combination with prednisone for the treatment of men with metastatic castration-resistant prostate cancer.
Cross-Resistance to Docetaxel and Cabazitazel in CRPC Mediated by ABCB1 Gene
Results of an investigation indicate that resistance to docetaxel and cabazitaxel (Jevtana) in patients with castration-resistant prostate cancer is mediated by a common mechanism, overexpression of the ABCB1 gene.
PROSPER CRPC Data to Be Released 2 Years Earlier Than Expected
Astellas Pharma and Pfizer have announced that phase III results from the PROSPER trial of enzalutamide (Xtandi) in men with nonmetastatic castration-resistant prostate cancer will be ready later this year.
Docetaxel Combined With Dexamethasone Shows PSA Response in Patients With CRPC
A recent phase II trial demonstrated that the combination of docetaxel-based chemotherapy and dexamethasone showed significantly high PSA responses compared with previous studies in patients with CRPC.
Raoul S. Concepcion, MD, discusses the new era of molecular testing and screening and how it has impacted the field of prostate cancer thus far. 
Publication Bottom Border
Border Publication